Biocellvia went to the USA in order to meet its American Market (Boston and San Francisco)
Biocellvia flew to its American market in March 18
avril 13, 2018
Further validation for Biocellvia’s digital image analysis in new scientific article published by Gustave Roussy in collaboration with Biocellvia
Further validation for Biocellvia’s digital image analysis in new scientific article published by Gustave Roussy
mai 14, 2018
Show all

Biocellvia will be at BIO18

Biocellvia will take part to BIO18 : the 2018 BIO International Conference

Biocellvia will take part in the 2018 BIO International Convention which will take place in Boston from June 4th to 7th. The BIO International Convention is the biggest global event for the pharmaceutical industry and attracts the biggest names in biotech. It provides insights and inspiration on the major trends affecting the industry. The event features keynotes and sessions from key policymakers, scientists, CEOs, and celebrities.

BIO18 brings us great opportunities

BIO18 is an important annual event for Biocellvia as it offers us invaluable networking and partnering opportunities. Last year, we took part in BIO17 in San Diego and successfully showcased our digital analysis service tailored for idiopathic pulmonary fibrosis. As a result we heightened market awareness of our innovative, breakthrough technology, and many of our current customers embraced our value-added services. This year, BIO18 will enable us to further broaden and expand our appeal within the biotech and pharma community, and we plan to set up meetings with many companies who are already interested in our services.

BIO18: annual event to present our innovation

This year, we will present the latest updates in our program development and bring a spotlight on our newest offerings in expanded indications. Our research and development team tirelessly pursues scientific rigor and is always pushing the boundaries of cutting-edge image analysis solutions based on machine learning. Biocellvia is now well-known and widely acknowledged for our expertise in respiratory disease research. This year, we will unveil our novel software for emerging diseases such as NASH. Furthermore, we look forward to discussing with potential partners and collaborators to apply our AI know-how in oncology.

Laisser un commentaire

Votre adresse de messagerie ne sera pas publiée. Les champs obligatoires sont indiqués avec *